Wikipedia
Tofogliflozin
Tofogliflozin ( USAN, codenamed CSG452) is an experimental drug for the treatment of diabetes mellitus and is being developed by Chugai Pharma in collaboration with Kowa and Sanofi. It is an inhibitor of subtype 2 sodium-glucose transport protein ( SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. , the drug is in Phase III clinical trials.